GSK Gsk Plc

1,733.50

5.00 (0.29%)

03 May 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Gsk Plc	LSE:GSK	London	Ordinary Share	GB00BN7SWP63	ORD 31 1/4P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	5.00	0.29%	1,733.50	1,732.50	1,733.00	1,739.50	1,724.50	1,733.00	4,237,056	16:35:18

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	30.33B	4.93B	1.1970	14.48	71.35B

GlaxoSmithKline's Belantamab Mafodotin Gets Recommendation From FDA Panel

15/07/2020 7:47am

Dow Jones News

Gsk (LSE:GSK)
Historical Stock Chart

From May 2019 to May 2024

   By Adria Calatayud

GlaxoSmithKline PLC said Wednesday that a U.S. Food and Drug Administration committee has voted in favor of its belantamab mafodotin antibody drug as therapy for the treatment of relapsed or refractory multiple myeloma.

The FDA's oncologic drugs advisory committee voted in favor of a positive benefit-risk profile for the drug to help patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, the British pharmaceutical company said. The FDA will consider the recommendation of the committee but isn't obligated to follow it, GSK said.

Belantamab mafodotin isn't currently approved for use anywhere in the world, the company said.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

July 15, 2020 02:32 ET (06:32 GMT)